Plain-English translation of NCT07914764 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new medical imaging scan called 68Ga-YQ-CC05 to see if it can safely help doctors find three specific types of cancer earlier than current methods. The scan uses a small amount of radioactive material that targets cancer cells, similar to other imaging scans you may have heard of. Researchers want to confirm that this new scan is safe and works well for patients with medullary thyroid cancer, small cell lung cancer, or stomach cancer.
Current imaging methods like CT and MRI scans don't always catch these cancers as early as doctors would like. This medication is designed to make cancer cells 'light up' on imaging so doctors can spot tumors sooner, when treatment is often most effective.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital for an imaging appointment where you receive an injection of the new radioactive medication, then have a special scanning camera take pictures to see if it can detect your cancer. The trial team will monitor your health and safety closely, checking your blood work and kidney function before and after the scan. Your participation helps researchers determine whether this new imaging method is both safe and effective for finding these cancers earlier.
AI-generated summary from trial data · Nov 6, 2026 · Not medical advice
China
Sponsor
Nanjing First Hospital, Nanjing Medical University
Enrollment target
~20 participants
Started
August 2026
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Feng Wang
Nanjing First Hospital, Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.